This study focuses on evaluating a medication called deucravacitinib (also known as BMS-986165) for treating moderate to severe plaque psoriasis in young people between 12 and 18 years old. Plaque psoriasis is a skin condition that causes red, thick, scaly patches on the skin. The purpose of this research is to determine how well the medication works and how safe it is for adolescent patients.
The study will test deucravacitinib against placebo in participants who have had plaque psoriasis for at least 6 months and who could benefit from whole-body treatment. The medication comes in the form of film-coated tablets that are taken by mouth. During the study, researchers will monitor how the skin condition improves and track any changes in participants’ health.
The main focus will be on measuring improvements in the skin condition after 16 weeks of treatment. The study will also look at how the medication affects participants’ growth and development. Throughout the study, doctors will regularly check participants’ overall health, including their height, weight, and physical development.
Belgium 
Germany 
Hungary 
Italy 
Poland 
Romania 
Spain 
